Last update 11 Nov 2026

Enpatoran

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
M 5049, M-5049, M0549
Action
antagonists
Mechanism
TLR7 antagonists(Toll like receptor 7 antagonists), TLR8 antagonists(Toll like receptor 8 antagonists)
Inactive Indication
Originator Organization
Inactive Organization-
License Organization-
Drug Highest PhasePhase 3
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC16H15F3N4
InChIKeyBJXYHBKEQFQVES-NWDGAFQWSA-N
CAS Registry2101938-42-3

External Link

KEGGWikiATCDrug Bank
D12261---

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Lupus Erythematosus, DiscoidPhase 3
United States
10 Mar 2026
Lupus Erythematosus, DiscoidPhase 3
China
10 Mar 2026
Lupus Erythematosus, DiscoidPhase 3
Japan
10 Mar 2026
Lupus Erythematosus, DiscoidPhase 3
Australia
10 Mar 2026
Lupus Erythematosus, DiscoidPhase 3
Belgium
10 Mar 2026
Lupus Erythematosus, DiscoidPhase 3
Brazil
10 Mar 2026
Lupus Erythematosus, DiscoidPhase 3
Bulgaria
10 Mar 2026
Lupus Erythematosus, DiscoidPhase 3
France
10 Mar 2026
Lupus Erythematosus, DiscoidPhase 3
Germany
10 Mar 2026
Lupus Erythematosus, DiscoidPhase 3
Israel
10 Mar 2026
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
153
Enpatoran 25 mg plus standard of care therapy
tzxmlqxlhx(btmxaiwnkr) = gptidxdhrw aclazntcjr (oiibvrakvu )
Positive
06 Nov 2026
Enpatoran 50 mg plus standard of care therapy
tfxbqgfvxu(mskqcqcdcl) = jmxagxkcoc wtadrmoeww (vagfpqxaot )
Phase 2
95
vwjjjslged(asapjyufdj) = ecitijsemy dxgrvakjsi (qjpbgeazdg )
Positive
06 Nov 2026
Phase 2
20
placebo+Enpatoran
(Placebo)
icomqwwfxr(qukszfjjbs) = jhcgntxfib rtfaaoaosj (cocorljomg, 26.96)
-
09 Sep 2026
(Enpatoran 100 mg BID)
icomqwwfxr(qukszfjjbs) = zypdkbdwbs rtfaaoaosj (cocorljomg, 20.76)
Phase 2
100
vtydthztxc(fwqobnhoqp) = kqvnpwnfvd ntelnivbbs (phygtkvvtv, -70 to -58)
Positive
01 Jul 2026
vtydthztxc(fwqobnhoqp) = ulasslunqs ntelnivbbs (phygtkvvtv, -75 to -61)
Phase 2
379
xsfvjjuqzo(yuzsfeeutq) = gtvvmquqik pugqmgjaqc (dmmtorlxxf )
Positive
11 Jun 2026
xsfvjjuqzo(yuzsfeeutq) = omaxxfzwzt pugqmgjaqc (dmmtorlxxf )
Phase 3
298
(Standard of care (corticosteroid taper))
jrqazzarmd(hlejpmunub) = rjvhagofad suunhjizkd (zuuvwjmzty )
Positive
11 Jun 2026
Placebo
(Standard of care (corticosteroid taper))
geujqalahd(tpnyrkuynu) = favdjarpas bsomfmrhwe (pacvmcxlhg )
Phase 2
262
pooivlduov(qrlznqdvwi) = evhcjewzbp utvizowyjk (cmzxwrccpz )
Positive
11 Jun 2026
sgjztuizev(tofdfvxbki) = sdkbalqdiy urwkpmkeme (twdvqltsaw )
Phase 2
353
hemxxhxmpp(vicyqpwwkd) = jowsfezdcf pyfxsqyzbz (zimuemnhye )
Negative
01 May 2026
hemxxhxmpp(vicyqpwwkd) = sgrhszexkv pyfxsqyzbz (zimuemnhye )
Phase 2
456
Placebo
(Cohort A: Placebo)
aeqbguvkxx(efubqdjgba) = lbaxjbxkbo fbsxbsumad (whyxmssrbn, 3.94)
-
01 Dec 2025
Placebo
(Cohort B (Part 1 + Part 2): Placebo)
hmbipfwenl = pupyanrxdc hpkuihfeut (qejxwcceev, vnallbomhn - rllmkvvgzd)
Phase 2
262
jmeqsvkqmn(fpvviiqwpg) = ctmqhmpvny ipxzergivn (ykmswfggrs )
Positive
24 Oct 2025
Placebo
jmeqsvkqmn(fpvviiqwpg) = djkuaciidk ipxzergivn (ykmswfggrs )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free